Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2023 | Switching from high-dose eculizumab to weight-based ravulizumab in patients with PNH

Morag Griffin • 23 Apr 2023
BSH 2023
Non-Malignant Paroxysmal Nocturnal Hemoglobinuria Antibodies Eculizumab Ravulizumab
ALXN1210-PNH-401

Morag Griffin, MBChB, BMSc(hons), MRCP UK, FRCPath, Leeds Teaching Hospitals NHS Trust, Leeds, UK, discusses interim results from the ALXN1210-PNH-401 study (NCT04320602) assessing the safety of switching from high-dose eculizumab to weight-based dosing of ravulizumab to treat patients with paroxysmal nocturnal hemoglobinuria (PNH). Dr Griffin explains the justification for this study, identifies the primary endpoints, and shares promising data collected thus far. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Advisory board/lecture fees: Novartis, Amgen, Alexion Astrazeneca, Sobi
Consultancy: Biocryst, Regeneron

More from Morag Griffin

1:43
The changing treatment landscape of PNH: novel agents and combinations
Morag Griffin • 23 Apr 2023

Related Videos

2:01
The MDT in the new era of gene therapy for hemoglobinopathies
Mattia Algeri • 15 Apr 2024
2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals